ProteoMiner™ and SELDI-TOF-MS: A robust and highly reproducible combination for biomarker discovery from whole blood serum

Archives of Physiology and Biochemistry

Volumn 116, Issue 4-5, 2010, Pages 174-180

  Frbel, Julia ^a   Hartwig, Sonja ^a   Paßlack, Waltraud ^a   Eckel, Jrgen ^a   Haas, Rainer ^a   Czibere, Akos ^a   Lehr, Stefan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

2 DE; ProteoMiner; SELDI TOF; Serum fractionation; Serum proteome

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEOME;

ARTICLE; BLOOD; CHEMISTRY; FRACTIONATION; HUMAN; IMAGE PROCESSING; MASS SPECTROMETRY; METHODOLOGY; PROTEIN MICROARRAY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CHEMICAL FRACTIONATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; PROTEIN ARRAY ANALYSIS; PROTEOME; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STATISTICS AS TOPIC;

EID: 78649297298     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2010.501082     Document Type: Article

References (21)

1. Aivado M, Spentzos D, Alterovitz G, Out HH, Grall F, Giagounidis AA, Wells M, Cho JY, Germing U, Czibere A et al. (2005). Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-fight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profling. Clin Chem Lab Med 43(2):133-40.
2. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH et al. (2007). Serum proteome profling detects myelodysplastic syndromes and identifes CXC chemokine ligands 4 and 7 as markers for advanced disease. PNAS 104(4):1307-12.
3. Allen J, Davey HM, Broadhurst D, Heald JK, Rowland JJ, Oliver SG, Kell DB (2003). High-throughput classifcation of yeast mutants for functional genomics using metabolic footprinting. Nat Biotechnol 21(6):692-6.
4. Anderson NL, Anderson NG. (2002). Te human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845-67.
5. De Bock M, de Seny D, Meuwis MA, Chapelle JP, Louis E, Malaise M, Merville MP, Fillet M. (2010). Challenges for biomarker discovery in body fuids using SELDI-TOF-MS. J Biomed Biotechnol epub ahead of print doi:10.1155/2010/ 906082. Review. E-pub ahead of print.
6. Engwegen JYMN, Mehra N, Haanen JBAG, Bonfrer JMG, Schellens JHM, Voest EE, Beijnen JH. (2007). Validation of SELDI-TOF MS serum protein profles for renal cell carcinoma in new populations. Lab Invest 87(2):161-72.
7. Gast MCW, Engwegen JYMN, Schellens JHM, Beijnen JH. (2008). Comparing the old and new generation SELDI-TOF MS: Implications for serum protein profling. BMC Med Genomics 1(4):1-12.
8. Guerrier L, Righetti PG, Boschetti E. (2008). Reduction of dynamic protein concentration range of biological extracts for the discovery of low-abundance proteins by means of hexapeptide ligand library. Nat Protoc 3(5):883-90.
9. ™): An innovative fractionation tool for diferential quantitative clinical proteomics. Arch Physiol Biochem 115(3):155-60.
10. Huang H, Stasyk T, Morandell S, Mogg M, Schreiber M, Feuerstein I, Huck CW, Stecher G, Bonn GK, Huber LA. (2005). Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoafnity depletion under partly denaturing conditions. Electrophoresis 26(14):2843-9.
11. Ishida Y, Yamashita K, Sasaki H, Takajou I, Kubuki Y, Morishita K, Tsubouchi H, Okayama A. (2008). Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry. Cancer Lett 271(1):167-77.
12. Kiehntopf M, Siegmund R, Deufel T. (2008). Use of SELDI-TOF mass spectrometry for identifcation of new biomarkers: potential and limitations. Clin Chem Lab Med 45(11):1435-49. Review.
13. Kwak J, Tian-Ze M, Yoo MJ, Choi BH, Kim HG, Kim SR, Yim CY, Kwak YG. (2004). Te comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 32(9):836-42.
14. Lehr S, Kotzka J, Avci H, Knebel B, Müller S, Hanisch FG, Jacob S, Haak C, Susanto F, Müller-Wieland D. (2005). Efect of sterol regulatory element binding protein-1a on the mitochondrial protein pattern in human liver cells detected by 2D-DIGE. Biochemistry 44(13):5117-28.
15. Mohamedali A, Guinn B, Sahu S, Tomas NS, Mufti GJ. (2009). Serum profling reveals distinctive proteomic markers in chronic myeloid leukaemia patients. Br J Haematol 144(2):362-5.
16. Purohit PV, Rocke DM. (2003). Discriminant models for highthroughput proteomics mass spectrometer data. Proteomics 3(9):1699-703.
17. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GBI, Tammen H et al. (2005). HUPO plasma proteome project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 5(13):3262-77.
18. Tulasiraman V, Lin S, Gheorghiu L, Lathrop J, Lomas L, Hammond D, Boschetti E. (2005). Reduction of the concentration diference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 26:3561-71.
19. Trimpin S, Inutan ED, Herath TN, McEwen CN. (2010). Matrixassisted laser desorption/ionization mass spectrometry method for selectively producing either singly or multiply charged molecular ions. Anal Chem 82(1):11-5.
20. Unwin RD, Whetton AD. (2007). How will haematologists use proteomics? Blood Reviews 21(6):315-326.
21. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJO, Johnson PJ, Martin A. (2006). Identifcation of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94(12):1898-905.